Research & Development
PreveCeutical Medical Inc., (“PREV”), as a health and wellness company is focused on utilising nature and science for the benefit of health-conscious consumers. With its vested interest in the preventive health sector, PREV, in collaboration with its partners, researches and develops innovative solutions that will provide consumers with options for preventive and curative therapies.
Dual Gene Therapy
a dual gene therapy targeting both diabetes and obesity.
The Company’s advantage is demonstrated proof of concept. Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the gene target implicated in both diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalised levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer:Dr. Harry Parekh, PhD, MRPharmS
Sol-gel Delivery Platform
for nose-to-brain delivery of therapeutic compounds
Developing what we believe will be the first FDA approved, CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-Gels are taken via nasal (systemic) administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines – eliminating first pass metabolism – and may dramatically improve bioavailability – even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
We expect to have our delivery platform fully tested, approved and ready for market deployment with licensed medical marijuana company partners in approximately 18 months.
Nature Identical™ Peptides
From the Caribbean Blue Scorpion Venom
to assist with cancer-targeted treatment
We plan to identify active peptides that are providing the immune boosting, pain relieving, and tumour selective properties, then test what happens when used on various abnormal cells like brain, lung and breast cancers.
A preclinical research and development program is now underway. It was designed and is being directed by our Chief Science Officer, Dr. Mak Jawadekar, PhD.
PreveCeutical, and partner Uniquest, will screen peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours. Our initial focus will be on targeting a very aggressive form of brain cancer (glioma). From there we plan to extend the program to screen our library of nature identical peptides in a high throughput screening (HTS) manner across a range of other cancers.
Engineering Peptide Therapeutics
for Non-Addictive Analgesia
PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a letter of intent proposing to expand the use of their disulfide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.
Dr Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example, when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.